Drug intelligence / Profile preview

pinoxin

Development stage: Phase 2
Lead developer: Fudan University
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

Pinoxin is a hydrogen-donor modified superoxide dismutase (SOD) developed as a topical skin protective agent. It is designed to prevent radiation-induced skin injury by neutralizing reactive oxygen species (ROS) generated during radiotherapy. Superoxide dismutase is an enzyme that catalyzes the dismutation of the superoxide radical into ordinary molecular oxygen and hydrogen peroxide. The modification with a hydrogen donor is intended to enhance its antioxidant capacity and stability. It has been studied in multicenter clinical trials led by Fudan University for patients undergoing radiation therapy to reduce the incidence of grade 2 or greater skin injury.

Brand names: Pinoxin
Other names: Hydrogen-Donor Modified SODHydrogen-Donor Modified Superoxide Dismutase

Beyond the preview

Go deeper on pinoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pinoxin.

Explore the full profile